Blood Transfusion - 4 2018 (July - August)
Second-line therapy in paediatric warm autoimmune haemolytic anaemia. Guidelines from the Associazione Italiana Onco-Ematologia Pediatrica (AIEOP)
Authors:  Saverio Ladogana, Matteo Maruzzi, Piera Samperi, Annalisa Condorelli, Maddalena Casale, Paola Giordano, Lucia D. Notarangelo, Piero Farruggia, Fiorina Giona, Agostino Nocerino, Silvia Fasoli, Maria L. Casciana, Maurizio Miano, Fabio Tucci, Tommaso Casini, Paola Saracco, Wilma Barcellini, Alberto Zanella, Silverio Perrotta, Giovanna Russo
Pages:  359-362
To cite this article:  Blood Transfus 2018; 16: 352-8
Doi:  10.2450/2018.0024-18
Published online:  13/04/2018

Autoimmune haemolytic anaemia (AIHA) is a rare condition in children caused by the presence of auto-antibodies directed against red blood cell surface antigens, leading to premature red cell destruction1,2.  It is classified as warm, cold, including cold haemagglutinin disease and paroxysmal cold haemoglobinuria, or mixed, according to the thermal range of the auto-antibody. AIHA can be idiopathic or secondary. The overall annual incidence is reported to be 1-3 cases/100,000 people and approximately 0.2 cases/1,000,000 individuals less than 20 years of age3-7.  […]
Full Text Download Back
Share this article: